10
Views
2
CrossRef citations to date
0
Altmetric
Original Article

Chemotherapy Consisting of Cisplatin, Epirubicin, and Cyclophosphamide in Advanced Ovarian Carcinoma

, , , &
Pages 1-5 | Published online: 11 Jun 2009

References

  • Italian multicenter breast study with epirubicin. Phase III randomized study of fluorouracil. epirubicin, and cyclophosphamide vs fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: An Italian multicentre trial. J Clin Oncol 1988; 6: 976–982
  • The French Epirubicin Study Group: A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin?. J Clin Oncol. 1988; 6: 679–688
  • Hernadi Z, Juhasz B, Pokar A, et al. Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'epi-adriamycin in the treatment of advanced ovarian cancer. Int J Gynecol Obst 1988; 27: 199–204
  • Wils J, Blijham G, Naus A, et al. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma?. J Clin Oncol. 1986; 4: 1068–1073
  • Wils J. Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and Chemotherapy consisting of cisplatin, doxorubicin. and cyclophosphamide. Oncology 1990; 47: 115–120
  • Ten Bokkel Huinink WW. Current status of chemotherapy fur advanced ovarian carcinoma?. Eur J Cancer Clin Oncol. 1988; 24: 583–585
  • The Ovarian Cancer Meta-Analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma; a meta-analysis?. J Clin Oncol. 1991; 9: 1668–1674
  • Neijt JP, ten Bokkel Huinink WW, van der Burg MEL, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987; 5: 1157–1168

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.